Graham Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-588	Closed	-$234K	–	1141
2025 Q4	$234K	Sell	588 -2,427	-80%	-$1.07M	0.01%	971
2025 Q3	$1.37M	Sell	3,015 -135	-4%	-$55K	0.05%	297
2025 Q2	$1.03M	Buy	3,150 +1,240	+65%	+$343K	0.03%	573
2025 Q1	$516K	Sell	1,910 -440	-19%	-$113K	0.02%	793
2024 Q4	$553K	Sell	2,350 -1,260	-35%	-$331K	0.02%	698
2024 Q3	$993K	Buy	3,610 +1,130	+46%	+$294K	0.03%	469
2024 Q2	$603K	Sell	2,480 -5,783	-70%	-$913K	0.02%	529
2024 Q1	$1.23M	Buy	+8,263	New	+$1.38M	0.04%	363
2023 Q4	–	Sell	-1,427	Closed	-$253K	–	980
2023 Q3	$253K	Sell	1,427 -342	-19%	-$65.3K	0.01%	778
2023 Q2	$336K	Buy	+1,769	New	+$351K	0.01%	648
2022 Q4	–	Sell	-11,940	Closed	-$2.39M	–	1031
2022 Q3	$2.39M	Sell	11,940 -2,525	-17%	-$482K	0.1%	173
2022 Q2	$2.11M	Buy	+14,465	New	+$2.05M	0.1%	194